Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (331-340 of 404) with videos related to

Pageof 41
Sort By:
Nature Genetics|September 15, 2009
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyVijayaprakash Suppiah, Max Moldovan, Golo Ahlenstiel, et al.
The Lancet. Gastroenterology & Hepatology|May 9, 2021
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort studyBehzad Hajarizadeh, Jason Grebely, Marianne Byrne, et al.
Open Forum Infectious Diseases|July 10, 2024
Long-acting HIV Treatments: Study Design, Logistics, and AccessNicholas A Murdock, Nayri E Alajaji, Robin Schaefer, et al.
Hepatology Communications|June 4, 2020
Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug ResistanceMark W Douglas, Enoch S E Tay, Dao Sen Wang, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 19, 2017
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapseFrançois M J Lamoury, Angelica Soker, Danica Martinez, et al.
The International Journal on Drug Policy|June 22, 2017
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE studyHåvard Midgard, Behzad Hajarizadeh, Evan B Cunningham, et al.
The International Journal on Drug Policy|November 3, 2018
Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in AustraliaSahar Bajis, Lisa Maher, Carla Treloar, et al.
Hepatology (Baltimore, Md.)|January 23, 2014
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological responseJacinta A Holmes, Stuart K Roberts, Rachel J Ali, et al.
The International Journal on Drug Policy|August 19, 2015
Recommendations for the management of hepatitis C virus infection among people who inject drugsJason Grebely, Geert Robaeys, Philip Bruggmann, et al.
Plos One|April 4, 2015
Patterns of hepatitis C virus RNA levels during acute infection: the InC3 studyBehzad Hajarizadeh, Bart Grady, Kimberly Page, et al.
Pageof 41

Showing results (331-340 of 404) with videos related to

Sort By:
Pageof 41
Nature Genetics|September 15, 2009
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyVijayaprakash Suppiah, Max Moldovan, Golo Ahlenstiel, et al.
The Lancet. Gastroenterology & Hepatology|May 9, 2021
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort studyBehzad Hajarizadeh, Jason Grebely, Marianne Byrne, et al.
Open Forum Infectious Diseases|July 10, 2024
Long-acting HIV Treatments: Study Design, Logistics, and AccessNicholas A Murdock, Nayri E Alajaji, Robin Schaefer, et al.
Hepatology Communications|June 4, 2020
Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug ResistanceMark W Douglas, Enoch S E Tay, Dao Sen Wang, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 19, 2017
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapseFrançois M J Lamoury, Angelica Soker, Danica Martinez, et al.
The International Journal on Drug Policy|June 22, 2017
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE studyHåvard Midgard, Behzad Hajarizadeh, Evan B Cunningham, et al.
The International Journal on Drug Policy|November 3, 2018
Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in AustraliaSahar Bajis, Lisa Maher, Carla Treloar, et al.
Hepatology (Baltimore, Md.)|January 23, 2014
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological responseJacinta A Holmes, Stuart K Roberts, Rachel J Ali, et al.
The International Journal on Drug Policy|August 19, 2015
Recommendations for the management of hepatitis C virus infection among people who inject drugsJason Grebely, Geert Robaeys, Philip Bruggmann, et al.
Plos One|April 4, 2015
Patterns of hepatitis C virus RNA levels during acute infection: the InC3 studyBehzad Hajarizadeh, Bart Grady, Kimberly Page, et al.
Pageof 41